title: A comparison of allografting with autografting for newly diagnosed myeloma.
abstract: BACKGROUND
  In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts.
  
  
  METHODS
  We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival.
  
  
  RESULTS
  After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P<0.001). The cumulative incidence rates of grades II, III, and IV graft-versus-host disease (GVHD) combined and of grade IV GVHD in the autograft-allograft group were 43% and 4%, respectively. Overall, 21 of 58 patients (36%) were in complete remission after a median follow-up of 38 months (range, 10 to 72) after allografting. Of the 46 patients who received two autografts, 25 (54%) died.
  
  
  CONCLUSIONS
  Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987 [ClinicalTrials.gov].).
authors.affiliation: San Giovanni Battista Hospital, University of Turin, Turin, Italy. benedetto.bruno@unito.it
authors.forename: Benedetto
authors.initials: B
authors.lastname: Bruno
authors.forename: Marcello
authors.initials: M
authors.lastname: Rotta
authors.forename: Francesca
authors.initials: F
authors.lastname: Patriarca
authors.forename: Nicola
authors.initials: N
authors.lastname: Mordini
authors.forename: Bernardino
authors.initials: B
authors.lastname: Allione
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Carnevale-Schianca
authors.forename: Luisa
authors.initials: L
authors.lastname: Giaccone
authors.forename: Roberto
authors.initials: R
authors.lastname: Sorasio
authors.forename: Paola
authors.initials: P
authors.lastname: Omedè
authors.forename: Ileana
authors.initials: I
authors.lastname: Baldi
authors.forename: Sara
authors.initials: S
authors.lastname: Bringhen
authors.forename: Massimo
authors.initials: M
authors.lastname: Massaia
authors.forename: Massimo
authors.initials: M
authors.lastname: Aglietta
authors.forename: Alessandro
authors.initials: A
authors.lastname: Levis
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallamini
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.forename: Rainer
authors.initials: R
authors.lastname: Storb
authors.forename: Giovannino
authors.initials: G
authors.lastname: Ciccone
authors.forename: Mario
authors.initials: M
authors.lastname: Boccadoro
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000145:classification / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D015999:Multivariate Analysis; D035781:Siblings; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous